Try our Advanced Search for more refined results

In re Lantus Direct Purchaser Antitrust Litigation

  1. January 05, 2023

    Lantus Buyers Line Up As Plaintiffs In Recast Class Action

    Lantus insulin pen buyers are hopping on board the proposed class action-turned direct lawsuit as plaintiffs after counsel for the aggrieved medication buyers realized that the litigation accusing Sanofi-Aventis of anti-competitive behavior wasn't suited to class treatment.

  2. September 14, 2022

    Sanofi Puerto Rico Unit Excused From Insulin Antitrust Case

    A Puerto Rico subsidiary of Sanofi-Aventis cannot be held liable for any alleged antitrust violations by its parent company in a suit accusing the pharmaceutical giant of improperly listing patents for the injector pen of lucrative diabetes drug Lantus, a Boston federal judge ruled Wednesday.

  3. June 14, 2021

    Insulin Pen Buyers Can Name Sanofi's Puerto Rico Unit In Suit

    Lantus insulin pen buyers can file a new antitrust class action against Sanofi-Aventis in order to name the drugmaker's Puerto Rico subsidiary as a defendant and two more companies as plaintiffs, a Massachusetts federal magistrate has ruled.

  4. March 19, 2021

    Sanofi Says Insulin Pen Buyers Can't Expand Antitrust Case

    Lawyers for pharmaceutical giant Sanofi-Aventis U.S. LLC urged a Massachusetts federal judge Friday not to let buyers of its Lantus insulin pen add its "corporate cousin" in Puerto Rico to an antitrust class action, arguing the suit doesn't tie the subsidiary to the overarching alleged anti-competitive conduct.

  5. November 13, 2020

    Insulin Pen Buyers Say Sanofi Antitrust Suit Not Overly Broad

    Buyers of Sanofi-Aventis' Lantus insulin pen fought back Friday in Massachusetts federal court against the company's bid to trim their proposed antitrust class action on the grounds the buyer behind the case stopped purchasing the drug partway through the alleged anti-competitive scheme.

  6. October 20, 2020

    Sanofi Wants Antitrust Claims Over Insulin Pen Pared Down

    Sanofi-Aventis is trying to knock out a recently revived antitrust suit accusing it of improperly putting one of its insulin injector patents on an FDA list, which allowed the pharmaceutical company to preemptively sue over up-and-coming generics.

  7. August 26, 2020

    Lantus Buyers Demand Info On More Sanofi Injector Patents

    Buyers of Sanofi's Lantus insulin treatments told a Massachusetts federal court Wednesday the company has wrongly refused to hand over documents about a number of patents for an injector device after the First Circuit revived their antitrust case based on arguments surrounding a single patent.

  8. February 14, 2020

    1st Circ. Revives Sanofi Insulin Injector Antitrust Case

    The First Circuit has revived a proposed class action against Sanofi-Aventis, saying the pharmaceutical company must prove it acted in good faith when it wrongly placed a patent for an insulin injector on an FDA list if it hopes to evade antitrust liability.

  9. January 11, 2018

    Murky FDA Device Guidance Kills Sanofi Antitrust Suit

    Sanofi reasonably filed a patent for its insulin injector in the FDA's Orange Book, since the agency wasn't clear about whether it should, and rationally defended that patent against possible infringement, a Massachusetts federal magistrate judge said Wednesday when dismissing an antitrust suit over the conduct.

  10. September 26, 2017

    Sanofi Urges Judge To Dump Antitrust Suit Over Lantus

    Sanofi-Aventis urged a Massachusetts magistrate judge Tuesday to dismiss an antitrust suit over its Lantus diabetes treatments, arguing that it reasonably listed its products in the so-called Orange Book and that its patent litigation against Eli Lilly was not a sham.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!